Close Menu

NEW YORK (GenomeWeb) – The US Food and Drug Administration has expanded the labeling for Roche's Cobas EGFR Mutation Test v2 as a companion diagnostic that can analyze plasma samples from non-small cell lung cancer patients considering treatment with AstraZeneca's Tagrisso (osimertinib). 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.